Jaime L. Chase

Cooley advised IN8Bio on its $40 million initial public offering of 4,000,000 shares of common stock. IN8Bio, whose securities now trade on the Nasdaq Global Market under the symbol INAB, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell therapies. Partners Josh Kaufman, Jaime Chase and Josh Rottner led the Cooley team.

Cooley advised Sprinklr on its $292.6 million initial public offering of 18,287,500 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Sprinklr, whose securities now trade on the New York Stock Exchange under the symbol CXM, is the unified customer experience management platform for modern enterprises. Partners Nicole Brookshire, Josh Kaufman and Jaime Chase led the Cooley team.

Cooley advised Five Prime Therapeutics, a publicly traded clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, on its agreement to sell to Amgen in an all-cash transaction with an equity value of approximately $1.9 billion. Partners Jamie Leigh, Ian Nussbaum and Laura Berezin led the Cooley team advising Five Prime.

Cooley advised IonQ, a quantum computing hardware and software company, on its merger agreement with special purpose acquisition company dMY Technology Group III. Resulting in $650 million in gross proceeds, including $350 million from a fully committed PIPE, the transaction will make IonQ the first publicly traded pure-play hardware and software company in the quantum computing space. Partners Adam Ruttenberg, John McKenna, David Silverman, Jaime Chase and Mike Lincoln led the Cooley team advising IonQ.

Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock. Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.